EMA Authorised: Eribulin Baxter (Eribulin mesylate) — Baxter Holding B.V.

View source ↗

Summary

EMA authorised Eribulin Baxter (eribulin mesylate) for treatment of breast neoplasms and liposarcoma; the marketing authorisation holder is Baxter Holding B.V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Liposarcoma

Drugs mentioned

• Eribulin Baxter (eribulin mesylate)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms;Liposarcoma. MAH: Baxter Holding B.V.. Decision date: 24/02/2026